There is only one clinical study planned to investigate the effectiveness of some natural JAK-STAT inhibitor including boswellic acids, as supplemental therapy for treating RA and reducing the adverse effects of standard MTX treatment (https://clinicaltrials.gov/; NCT05788705; accessed on 3 April 2024). The gene discussed is SOAT1; the disease is rheumatoid arthritis.